<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071511</url>
  </required_header>
  <id_info>
    <org_study_id>PV4286</org_study_id>
    <nct_id>NCT02071511</nct_id>
  </id_info>
  <brief_title>Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation</brief_title>
  <acronym>ARDEVAT</acronym>
  <official_title>Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:

      With optimal medical therapy and repeated ablations, an additional renal denervation may have
      protective effects in terms of vegetative intrinsic activity and lead to a significant
      reduction in VT Burdens.

      Study design:

      Multicenter, randomized, prospective, single-blind clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study protocol:

      Catheter ablation of ventricular tachycardia versus combined catheter ablation of ventricular
      tachycardia and renal denervation.

      A total of 50 patients with ventricular tachycardia treated with ICD shocks or ATP will be
      enrolled in this study. The randomization in the study is done before ablation.

      For the ablation, an arterial access is required in both groups. During a 30 minutes waiting
      time which will apply to both groups, renal denervation will be performed.

      In this period of time operators and staff will be blinded for the procedure, thereby they
      won't know if the patients will receive a renal denervation, in that way the investigators
      are avoiding a bias of future treatment of the patients.

      Follow up and repeat procedures:

      All Patients will be followed for a period of 3, 6, 9, 12 and 18 months after the procedure.

      Regular visits are done in the investigators office. The visit will include ICD
      Interrogation, VT documentation in ICD Holter, 24-hour Holter ECG or Tele-ECGs,
      echocardiography.

      Re- VT ablations are allowed at any time. In case of renal artery stenosis, denervation will
      not be performed. Drug therapy can be continued.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    results of the SYMPLICITY HTN 3 trial
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with adverse events such as recurrens of Ventricular Tachycardias or necessary Intracardiac shocks during 24 months follow up</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Ventricular extrasystoles and non-sustained Ventricular Tachycardias compared to the time prior to ablation during 24 months follow up</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of periprocedural complications</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation of ventricular arrhythmias</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ablation of ventricular arrhythmias + renal denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of ventricular arrhythmias</intervention_name>
    <description>control group: Ablation of ventricular arrhythmias</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of ventricular arrhythmias + renal denervation</intervention_name>
    <description>Intervention group: Ablation of ventricular arrhythmias + renal denervation</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Ischemic cardiomyopathy

          -  NYHA II-III

          -  Recurrent ventricular tachycardia, ICD interventions (shock or ATP)

          -  Obtained written informed consent

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Previous VT ablation

          -  NYHA IV

          -  Cardiopulmonary decompensation within the last 4 weeks

          -  Pregnant women or women of childbearing potential without a negative pregnancy test
             within 48 hours prior to treatment

          -  History of hemorrhagic diathesis or other coagulopathies

          -  Contraindication for oral anticoagulation

          -  Hyper- or hypothyroidism

          -  Drug or chronic alcohol abuse

          -  Has any condition that would make participation not be in the best interest of the
             subject

          -  Incompliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

